Legal Opinion
In re Zofran (Ondansetron) Prods. Liab. Litig.
District Court, District of Columbia
Decided July 25, 2019No. MDL No. 1:15-md-2657-FDSPublishedCited by 4 opinions
1Opinion of the Court
F. Dennis Saylor IV, United States District Judge
This is a multi-district litigation ("MDL") proceeding arising out of product-liability claims that the use of the drug Zofran (ondansetron ) by pregnant women caused certain types of birth defects in their children.
Defendant GlaxoSmithKline LLC ("GSK") has moved to compel the production of certain documents by plaintiffs and a third-party witness, April Zambelli-Weiner, Ph.D. Plaintiffs and Dr. Zambelli-Weiner have withheld the documents from production, contending that they are protected from discovery as attorney work product under Fed. R.…
2Cases cited5 opinions
- Federal Trade Commission v. Grolier Inc.Supreme Court of the United States · 1983
- United States v. Massachusetts Institute of TechnologyCourt of Appeals for the First Circuit · 1997
- In re Raytheon Securities LitigationDistrict Court, D. Massachusetts · 2003
- Bryan Corp. v. Chemwerth, Inc.District Court, D. Massachusetts · 2013
- Hoffman v. Owens-Illinois Glass Co., Textron, Inc.District Court, D. Massachusetts · 1985
3Cited by4 opinions
- Brown v. Amazon.com IncDistrict Court, W.D. Washington · 2025
- De Coster v. Amazon.com IncDistrict Court, W.D. Washington · 2025
- Flemming v. C R Bard IncorporatedDistrict Court, D. Connecticut · 2021
- Frame-Wilson v. Amazon.com IncDistrict Court, W.D. Washington · 2025